- Associated Press - Thursday, December 23, 2010

CONCORD, N.H. (AP) — New Hampshire is getting $1.7 million from two prescription drug manufacturers that billed the state’s Medicaid program for substandard or improperly marketed medications.

GlaxoSmithKline will pay the state $1.24 million because four drugs it marketed here between 2001-2005, including Paxil CR, did not meet strength and purity standards set by the FDA.

Drug maker Novartis will pay the state $489,000 because it promoted its anti-epileptic drug, Trileptal, for unapproved uses such as treatment of bipolar disorder and neuropathic pain.

Senior Assistant Attorney General Jeff Cahill said no New Hampshire patients suffered harm as a result of the drug frauds.